Regenesis

Company Overview

Snapshot

Founded in February 2023, Regenesis operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its innovative cartilage regeneration technology.

Business overview

Regenesis is a biomedical startup dedicated to revolutionizing the treatment of cartilage lesions. The company's core technology involves a unique biocompatible structure designed to enhance in situ cartilage regeneration through a minimally invasive procedure. This platform can be adapted for various medical conditions associated with cartilage damage, including hip and ankle lesions and Osteoarthritis (OA). Regenesis operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Biomaterials & Tissue Engineering.

Company Intelligence Q&A

What is Regenesis' primary focus?

Regenesis is focused on developing innovative solutions for cartilage regeneration, aiming to restore cartilage through minimally invasive procedures using a unique biocompatible structure.

What medical conditions does Regenesis' platform address?

The Regenesis platform is designed to address various medical conditions associated with cartilage damage, including hip and ankle lesions and Osteoarthritis (OA).

When was Regenesis founded?

Regenesis was founded in February 2023.

What is the current stage of Regenesis' product development?

Regenesis' product, the mESh Technology platform, is currently in the R&D stage.

What is Regenesis' primary business model?

Regenesis primarily operates with a B2B business model.